Recruiting NCT07703683
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: GLP-1 Receptor Agonists.
- Who it may be relevant to
- Registry conditions: Diabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .
Interventions
- Drug GLP-1 Receptor Agonists
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Primary outcome measures
- Prevalence of sarcopenia / sarcopenic obesity [Time frame: From February 2026 to december 2056]
Secondary outcome measures (4)
- Myokines levels in serum or plasma [Time frame: February 2026 to December 2056]
- Myokine expression [Time frame: February 2026 to December 2056]
- Prevalence of MASLD [Time frame: March 2026 to December 2056]
- Prevalence of MASH [Time frame: March 2026 to December 2056]
Eligibility criteria
Inclusion criteria
- Metabolic or endocrine disease
Exclusion criteria
- Known myopathy
- Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
- Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
- History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Belgium · 1 center
- Cliniques Universitaires Saint-Luc — Woluwe-Saint-Pierre - Sint-Pieters-Woluwe
Identifiers
NCT: NCT07703683 · 2025/29OCT/445